Drug intelligence / Profile preview

ModCAR-CD22

Development stage: Preclinical
Lead developer: Hauul Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ModCAR-CD22 is a preclinical-stage modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio. It is designed to target CD22-positive hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). The ModCAR platform utilizes a modular architecture intended to provide enhanced control and potentially multi-antigen targeting capabilities to improve the safety and efficacy of CAR-based treatments for blood cancers.

Other names: ModCAR-CD22ModCAR-CD-22ModCAR-CD 22

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on ModCAR-CD22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ModCAR-CD22.

Explore the full profile